These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23134556)

  • 1. Component pathogen inactivation: a critical review.
    Prowse CV
    Vox Sang; 2013 Apr; 104(3):183-99. PubMed ID: 23134556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
    Klein HG; Glynn SA; Ness PM; Blajchman MA;
    Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the use of pathogen-reduced human plasma and platelet concentrates.
    Seltsam A; Müller TH
    Br J Haematol; 2013 Aug; 162(4):442-54. PubMed ID: 23710899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
    Seghatchian J; Tolksdorf F
    Transfus Apher Sci; 2012 Apr; 46(2):221-9. PubMed ID: 22365926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of pathogen-inactivated plasma components.
    Prowse C
    Transfus Med Rev; 2009 Apr; 23(2):124-33. PubMed ID: 19304113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two pathogen reduction technologies--methylene blue plus light and shortwave ultraviolet light--effectively inactivate hepatitis C virus in blood products.
    Steinmann E; Gravemann U; Friesland M; Doerrbecker J; Müller TH; Pietschmann T; Seltsam A
    Transfusion; 2013 May; 53(5):1010-8. PubMed ID: 22905868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects.
    Irsch J; Seghatchian J
    Transfus Apher Sci; 2015 Apr; 52(2):240-4. PubMed ID: 25824703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.
    Drew VJ; Barro L; Seghatchian J; Burnouf T
    Blood Transfus; 2017 Oct; 15(6):512-521. PubMed ID: 28488960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathione.
    Laughhunn A; Huang YS; Vanlandingham DL; Lanteri MC; Stassinopoulos A
    Transfusion; 2018 Mar; 58(3):748-757. PubMed ID: 29322519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen inactivation technology: cleansing the blood supply.
    Klein HG
    J Intern Med; 2005 Mar; 257(3):224-37. PubMed ID: 15715679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials for pathogen reduction in transfusion medicine: a review.
    McClaskey J; Xu M; Snyder EL; Tormey CA
    Transfus Apher Sci; 2009 Dec; 41(3):217-25. PubMed ID: 19793679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing the financial impact of pathogen inactivation technology for platelet components: our experience.
    Girona-Llobera E; Jimenez-Marco T; Galmes-Trueba A; Muncunill J; Serret C; Serra N; Sedeño M
    Transfusion; 2014 Jan; 54(1):158-68. PubMed ID: 23656485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of bacterial risk: pathogen inactivation/detection of bacteria].
    Morel P; Naegelen C; Deschaseaux M; Bardiaux L
    Transfus Clin Biol; 2013 May; 20(2):109-14. PubMed ID: 23622837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogen inactivation: emerging indications.
    Kleinman S
    Curr Opin Hematol; 2015 Nov; 22(6):547-53. PubMed ID: 26390164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.
    Lozano M; Cid J
    Transfus Clin Biol; 2013 May; 20(2):158-64. PubMed ID: 23587612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains.
    Schmidt M; Hourfar MK; Sireis W; Pfeiffer U; Göttig S; Kempf VA; McDonald CP; Seifried E
    Transfusion; 2015 Sep; 55(9):2104-12. PubMed ID: 26013691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemovigilance data on the use of methylene blue virally inactivated fresh frozen plasma with the Theraflex MB-Plasma System in comparison to quarantine plasma: 11 years' experience.
    Politis C; Kavallierou L; Hantziara S; Parara M; Zervou E; Katsarou O; Hatzitaki M; Fountouli P; Gioka A; Tzioura K; Koumarianos S; Asariotou M; Richardson C
    Transfus Med; 2014 Oct; 24(5):316-20. PubMed ID: 25262924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.